Heart Failure (HF) is a multi-faceted and life-threatening syndrome characterized by
significant morbidity and mortality, poor functional capacity and quality of life, and high costs …

The heart failure syndrome has first been described as an emerging epidemic about 25
years ago. Today, because of a growing and ageing population, the total number of heart …

Importance Heart failure with preserved ejection fraction (HFpEF), defined as HF with an EF
of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 …

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of 64
million people globally. Although the incidence of HF has stabilised worldwide and seems to …

The Heart Failure Association of the European Society of Cardiology has published a
previous position paper and various guidelines over the past decade recognizing the value …

Heart failure (HF) is common and associated with a poor prognosis, despite advances in
treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co …

Cardiovascular disease (CVD) remains the leading cause of death worldwide, representing
a major health, social, and economic issue. Thyroid disorders are very common and affect> …

Research about heart failure (HF) has made major progress in the last years. We give here
an update on the most recent findings. Landmark trials have established new treatments for …

Heart failure (HF) is a leading cause of mortality. Failing hearts undergo profound metabolic
changes, but a comprehensive evaluation in humans is lacking. We integrate plasma and …

Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with
high binding affinity, high MR selectivity and a short plasma half-life. In two major endpoint …